https://www.selleckchem.com/ALK.html
s targeting patients prior to their first visit to healthcare professionals in reducing pre-diagnosis interval.We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public Assessment Reports, Summaries of Product Characteristics, and published randomized controlled trials (RCTs) on anti-cancer drugs approved by EMA
Like
Comment
Share
